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Abstract
Background: Rhoptries are specialized organelles from parasites belonging to the phylum Apicomplexa; they
secrete their protein content during invasion of host target cells and are sorted into discrete subcompartments
within rhoptry neck or bulb. This distribution is associated with these proteins’ role in tight junction (TJ) and
parasitophorous vacuole (PV) formation, respectively.
Methods: Plasmodium falciparum RON2 amino acid sequence was used as bait for screening the codifying gene
for the homologous protein in the Plasmodium vivax genome. Gene synteny, as well as identity and similarity
values, were determined for ron2 and its flanking genes among P. falciparum, P. vivax and other malarial parasite
genomes available at PlasmoDB and Sanger Institute databases. Pvron2 gene transcription was determined by
RT-PCR of cDNA obtained from the P. vivax VCG-1 strain. Protein expression and localization were assessed by
Western blot and immunofluorescence using polyclonal anti-PvRON2 antibodies. Co-localization was confirmed
using antibodies directed towards specific microneme and rhoptry neck proteins.
Results and discussion: The first P. vivax rhoptry neck protein (named here PvRON2) has been identified in this
study. PvRON2 is a 2,204 residue-long protein encoded by a single 6,615 bp exon containing a hydrophobic signal
sequence towards the amino-terminus, a transmembrane domain towards the carboxy-terminus and two coiled
coil a-helical motifs; these are characteristic features of several previously described vaccine candidates against
malaria. This protein also contains two tandem repeats within the interspecies variable sequence possibly involved
in evading a host’s immune system. PvRON2 is expressed in late schizonts and localized in rhoptry necks similar to
what has been reported for PfRON2, which suggests its participation during target cell invasion.
Conclusions: The identification and partial characterization of the first P. vivax rhoptry neck protein are described
in the present study. This protein is homologous to PfRON2 which has previously been shown to be associated
with PfAMA-1, suggesting a similar role for PvRON2.
Background
Of the five Plasmodium parasite species producing
human malaria, Plasmodium vivax causes 100 to
300 million clinical cases per year [1,2], representing
~40% of the population suffering from this disease.
Although P. vivax malaria has been considered to be
less severe than that produced by Plasmodium falci-
parum in clinical terms, several factors have highlighted
the need to search for new effective control measures to
counteract P. vivax infections, i.e. its ability to cause
chronic infections by inducing dormant forms present
in the liver (hypnozoites), increased severe manifesta-
tions caused by this parasite species and the emergence
of strains resistant to chemotherapeutic agents, such as
chloroquine [3,4]. Due to the difficulty of carrying out a
P. vivax continuous culture in vitro, this parasite has
been relatively less studied compared to other Plasmo-
dium species. To overcome this problem, a comparative
approach has been undertaken aimed at identifying and
characterizing in P. vivax parasite molecules involved in
target cell invasion previously described for other Plas-
modium species (mainly P. falciparum), and in recent
transcriptome studies of the P. vivax intraerythrocytic
development cycle [5].
The Plasmodium parasite life-cycle is very complex,
beginning with a larva-like structure (or sporozoite)
* Correspondence: mapatarr.fidic@gmail.com
1Fundación Instituto de Inmunología de Colombia FIDIC, Carrera 50 # 26-20,
Bogotá, Colombia
Full list of author information is available at the end of the article
Arévalo-Pinzón et al. Malaria Journal 2011, 10:60
http://www.malariajournal.com/content/10/1/60
© 2011 Arévalo-Pinzón et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
being injected by the Anopheles mosquito during its bite
in the search for a blood meal. The sporozoites then
migrate to the liver and invade hepatocytes, where they
rapidly reproduce and transform into thousands of
pear-like structures (merozoites). During the asexual
erythrocytic phase, which is responsible for the clinical
manifestations of the disease, merozoites invade red
blood cells (RBCs) very quickly through a process
mediated by multiple receptor-ligand interactions [6].
A large number of parasite proteins associated with this
type of interaction are stored in a set of specialized api-
cal organelles known as rhoptries, micronemes and
dense granules [7,8]. After initial contact with the RBC,
the parasite redirects its apical pole over the erythrocyte
membrane and sequentially releases the contents from
micronemes, rhoptries and then the dense granules [9].
These molecular events lead to tight junction (TJ) and
parasitophorous vacuole (PV) formation, as well as the
biochemical and functional remodelling of host cell
architecture [10].
A TJ is characteristic of members belonging to the
phylum Apicomplexa and can be seen as a ring-shaped
electro-dense structure by electron microscope; this
connects to the parasite’s actin-myosin motor [11] to
propel the parasite within the nascent PV, where it will
reside during the intraerythrocytic development cycle
[12]. Several microneme- and rhoptry-derived proteins,
such as reticulocyte-binding protein homologues (RH)
[13,14], erythrocyte-binding ligands (EBL) and the
MCP-1 protein [15] either form part or are associated
with the TJ.
Apical merozoite antigen 1 (AMA-1) is derived from
micronemes and is essential in invasion of most Api-
complexa studied so far [16,17]. It has been recently
described that it is associated with proteins derived
from the rhoptry neck in Toxoplasma gondii, such as
RON-2, -4, -5 and -8 in the TJ. A TJ organizational
model described by Besteiro et al in 2009 [18], proposed
that the parasite directly inserts some RON proteins
(also identified as AMA-1 associated proteins (AAPs))
into the host cell membrane, thus acting as additional
TgAMA-1 receptors. A clear interaction between the
TgRON2 C-terminal region and the AMA-1 ectodomain
(forming a crucial bridge between TgAMA-1 and the
rest of the AAPs) has been recently demonstrated
through different protein-protein interaction assays.
Moreover, inhibition assays using recombinant proteins
have shown that the RON2 and AMA-1 interaction is
critical for the entry to host cells [19,20].
Previous comparative analysis between T. gondii and
P. falciparum genomes has revealed the presence of
homologues for TgRON2, TgRON4 and TgRON5 pro-
teins in P. falciparum: PfRON2 (Pf14_0495), PfRON4
(Pf11_0168) and PfRON5 (MAL8P1.73), respectively.
PfRON2 [21], PfRON4 [22] and PfRON5 [23] are
located in the rhoptry neck and co-immunoprecipitate
with PfAMA-1 [21,22,24,25]. Furthermore, the PfRON2
protein and the PfAMA-1 ectodomain interaction has
already been characterized, as well as its importance for
erythrocyte invasion, suggesting that the mechanism
described in T. gondii could be conserved among differ-
ent members of the phylum Apicomplexa [19].
Studies with parasite lines expressing PfAMA-1 protein
mutants have shown that the Y251 residue, located
inside the hydrophobic channel, is absolutely essential for
PfAMA1/AAP complex formation [25]. Interestingly, an
invasion inhibition antibody known as 4G2, that recog-
nizes the domain II loop of PfAMA-1 [26], prevents
PfAMA1/AAP complex assembly through steric hin-
drance and/or by inducing a PfAMA-1 conformational
change which interferes with the AAP binding site
[25,27]. Likewise, the R1 peptide derived from a random
phage display peptide library and known for being a
powerful inhibitor of merozoite invasion of human RBCs
[28] acts by binding to the PfAMA-1 hydrophobic chan-
nel and blocking PfAMA1-AAPs complex formation [29].
These data suggest that the interaction of a vaccine can-
didate molecule such as PfAMA-1 with new rhoptry neck
components is critical during invasion of erythrocytes
and a better understanding of the molecular mechanisms
involved in this process might thus help in developing
new anti-malarial strategies.
Taking into account the importance and implication
of RONs in different parasites belonging to the phylum
Apicomplexa and based on previous studies carried out
in P. falciparum, the identification and characterization
of the first P. vivax rhoptry neck protein (PvRON2),
which is homologous to PfRON2, are described in the
present study. This protein is 2,204 amino acids-long
(~220 kDa molecular mass), displaying an apical expres-
sion in P. vivax late schizonts, which suggests its role
during invasion of target cells.
Methods
Bioinformatics methods
The search for a PfRON2 homologous gene in P. vivax
was carried out using the tBlastn tool in the P. vivax Sal-
1 strain genome [30]. The sequence having the greatest
score was selected as pvron2 putative gene. PlasmoDB
and Sanger Institute [31] databases were scanned for
pvron2 and pfron2 homologous genes in partial genomes
from other Plasmodium species (Plasmodium knowlesi,
Plasmodium chabaudi, Plasmodium yoelii and Plasmo-
dium berghei). Identity and similarity values between
P. falciparum - P. vivax and the other species were
obtained with ALignX and ClustalW tools [32]. The pre-
sence of a signal peptide was assessed by using SignalP
[33] and anchor regions were predicted using the
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PredGPI and TMHMM servers [34]. Repeat sequences
and domains were predicted with the sequence tandem
repeats extraction and architecture modelling software
(XSTREAM, variable ‘X’), the simple modular architec-
ture research tool (SMART) and GlobPlot tools [35-37].
Bepipred tool [38] and ANTHEPROT software [39] were
used for linear B epitope selection.
Nucleic acids source and extraction
The P. vivax Colombia Guaviare 1 (VCG-1) strain was
used as DNA, RNA and protein source. The strain was
cultured through successive passes in Aotus spp
monkeys from FIDIC’s Primate Station in Leticia, Ama-
zonas, as previously described [40] and according to the
conditions established by the Ministry of the Environ-
ment’s official Institute, Corpoamazonía (resolution
00066, September 13th 2006). Three to four mL of
P. vivax VCG-1-infected monkey’s blood were extracted;
a schizont-rich sample was then obtained by discontinu-
ous Percoll gradient (GE Healthcare, Uppsala, Sweden)
according to a previously described protocol [41].
A Wizard genomic DNA purification kit (Promega, Wis-
consin, USA) was used for genomic DNA extraction
(gDNA) following the manufacturer’s specifications.
Total RNA was extracted by the Trizol method [42] and
then treated with RQ1 RNase-free DNase (Promega,
Wisconsin, USA). Five microlitres of RNA were used as
cDNA synthesis template using the Superscript III
enzyme (Invitrogen, Carlsbad CA) and oligo (dT) pri-
mers in a 5-min cycle at 65°C, followed by 60 minutes
at 50°C and a final 15-min cycle at 70°C.
Primer design, cloning and pvron2 gene sequencing
The pvron-2 nucleotide sequence (PVX_117880),
reported in the PlasmoDB database, was used as tem-
plate for designing three sets of primers with GeneRun-
ner v3.05 software. PvRON2-pEXP-F1 5’-ATG ATA
AGTA CAA GGG AGG CAA AA-3’ and PvRON2-
pEXP-R1 5’-ATA TCT TTT GTT TCT CGT CCT G-3’
primers were used for amplifying region I, consisting of
amino acids 18 to 742. PvRON2-pEXP-F2 5’-ATG AAC
CCAT TAG TAT ATC ACG TG-3’ and PvRON2-
pEXP-R2 5’-CAG CAG TTT CAT CTTG GCC-3’ were
used for amplifying region II, consisting of amino acids
701 to 1560. Region III (amino acids 1517 to 2203) was
amplified with PvRON2-pEXP-F3 5’-ATG ACC AGG
GCT GAG AAA TTC G-3’ and PvRON2-pEXP-R3 5’-
CAC CTG TAT GCG GGC GTA-3’. Two primers were
used for amplifying the PvAMA-1 ectodomain (43-487
amino acids): PvAMA-1D 5’-ATG CCT ACC GTT
GAG AGA AGC A-3’ and PvAMA-1R 5’-TAG TAG
CAT CTG CTT GTT CG-3’.
PCR amplification was carried out using GoTaq Flexi
DNA polymerase enzyme (Promega) in a 25 μL final
reaction, according to manufacturer’s instructions.
Amplification conditions were as follows: a 7-min cycle
at 95°C, followed by 35 cycles of 1 min at 58°C, 3 min
at 72°C and 1 min at 95°C, and finally, a 10-min exten-
sion step at 72°C. Products were visualized on a 1%
agarose gel and then purified with a Wizard PCR preps
kit (Promega). PCR products obtained from cDNA were
cloned in the pEXP5-CT/TOPO expression vector using
TOPO TA cloning (Invitrogen, Carlsbad CA). Positive
clones were analysed by enzymatic restriction and
sequenced in an ABI PRISM 310 Genetic Analyser (PE
Applied Biosystems).
Peptide synthesis and polyclonal antibody production
Two linear B-cell epitope peptides were selected for pro-
ducing polyclonal antibodies against the PvRON2 protein
based on the following parameters: (1) high average
values for Parker’s antigenicity, hydrophilicity and solvent
accessibility obtained with Antheprot software [39],
(2) high values in results obtained with the Bepipred tool
(at default 0.35 threshold and 75% specificity) [38] and
(3) selected peptides had to be located in different por-
tions of the protein, with the aim of detecting different
fragments in case the PvRON2 protein was proteolyti-
cally processed. Selected peptides were synthesized by
solid-phase peptide synthesis (SPPS) using the tert-
butoxycarbonyl (t-Boc) strategy [43] and numbered
according to our institute’s serial numbering system as:
35519 (CG734YGRTRNKRYMHRNPGEKYKG753GC) and
35520 (CG1674KLQQEQNELNEEKERQRQEN1693GC).
Peptide 37870, derived from the N-terminal region
of PvAMA-1 protein (CG23RNQKPSRLTRSANNVL-
LE40GC), and 32416, derived from PvRhopH3 protein
(CG792SAGVGTVSTHSPATAARMGL811GC), were
synthesized by SPPS. Peptide 37870 has been shown to be
immunogenic in mice [44] and peptide 32416 has pre-
viously been used for polyclonal antibody production in
rabbits, followed by localization experiments for the
PvRhopH3 protein [45]. Synthesized peptides were ana-
lysed by reverse phase high performance liquid chromato-
graphy (RP-HPLC) and MALDI-TOF mass spectrometry
(Auoflex, Bruker Daltonics, Bremen, Germany). Cysteine
and glycine were added to the N- and C-termini during
synthesis to allow peptide polymerization. These peptides
were inoculated in mice and the obtained sera were used
for co-localization experiments as explained below.
Two New Zealand rabbits were selected (numbered 89
and 90) for obtaining polyclonal antibodies against
PvRON2 protein; they were negative for P. vivax-derived
protein recognition by Western Blot. Each rabbit was
subcutaneously inoculated with 500 μg of putative
PvRON2-derived peptide 35519 (rabbit 90) or peptide
35520 (rabbit 89), emulsified in Freund’s complete adju-
vant (FCA) on day 0. Booster immunizations on days
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20 and 40 were administered using the same peptides
emulsified in Freund’s incomplete adjuvant (FCI).
Rabbits’ sera were collected on day 60 and used for
further assays.
7-8 week old BALB/c strain mice were intraperitone-
ally (i.p.) immunized with 100 μg of peptide 37870 or
peptide 32416, emulsified in FCA. Three boosters
were given on days 30, 45 and 60 with 100 μg of FCI-
emulsified peptide. These animals were bled 15 days
after the last immunization and their sera were collected
for further assays. Immunizations and animal bleeding
were carried out following Colombian Ministry of
Health recommendations for handling live animals used
in research or experimentation.
Immunoblotting and immunofluorescence
Saponin-treated parasite lysate was separated by 10%
SDS-PAGE and proteins were then transferred to a
nitrocellulose membrane. The membrane was blocked
with a 5% milk solution in 0.05% PBS-Tween for one
hour to eliminate unspecific binding. The membrane
was cut into stripes for individual incubation with pre-
immune and hyper-immune sera (anti-PvRON2 polyclo-
nal antibodies) in 1:20 dilution for 90 min, followed by
incubation with phosphatase-coupled anti-rabbit IgG
(PIERCE, Rockford, IL, USA) in a 1:5,000 dilution for 60
min. A BCIP/NBT kit (Promega) was used as a revealing
solution, according to the manufacturer’s instructions.
Plasmodium vivax VCG-1 thick smears were used for
immunofluorescence assays and fixed with 4% v/v for-
maldehyde for 10 min. The slides were then permeabi-
lized for 10 min with 1% v/v Triton and blocked with a
1% BSA/PBS solution at 37°C. The slides were washed
several times with PBS and incubated with 300 μL of
anti-PvRON2 polyclonal serum (primary antibody) in a
1:40 dilution with either anti-PvAMA-1 in a 1:20 dilu-
tion or anti-PvRhopH3 in the same dilution for 60 min.
Fluorescein-labelled anti-rabbit IgG (FITC) (Vector
Laboratories, Burlingame, CA, USA) and rhodamine-
labelled anti-mouse IgG (Millipore, Billerica, MA, USA)
were used as secondary antibody for 60 min, followed
by three PBS washes. Parasite nuclei were stained with a
2 μg/mL solution of 4’,6-diamidino-2-phenylindole
(DAPI) for 20 minutes at room temperature and fluores-
cence was visualized in a fluorescence microscope
(Olympus BX51) using an Olympus DP2 camera and
Volocity software (Perkin Elmer, Waltham, MA, USA).
Results and Discussion
pvron2 identification and orthologous genes
The PfRON2 protein amino acid sequence (PF14_0495)
was used as template for scanning the P. vivax complete
genome, available in PlasmoDB (version 6.5), in the
search for the homologous PvRON2 encoding gene.
tBlastn analysis revealed a nucleotide sequence having a
high probability of containing the pvron2 gene located
in reading frame -2 between 2,221,529-2,214,921 bp,
contig CM000453. High similarity (61.7%) and identity
(47.8%) values were found between PfRON2 and
PvRON2 protein amino acid sequences, suggesting that
these two proteins share a common origin. pvron2
neighbouring genes located upstream and downstream
were also analysed, as well as their intron-exon organi-
zation; identity and similarity values were determined by
comparing P. falciparum and P. vivax protein sequences
(Figure 1). Similarity and identity values were found ran-
ging from 60.4%-98.3% and 42.7-96.6%, respectively, in
the analysed chromosomal region.
PfRON2 and PvRON2 orthologues were found in
P. knowlesi (PkRON2: PKH_125430), P. chabaudi
(PcRON2: PCAS_131900), P. berghei (PBANKA_131570)
and P. yoelii (Py06813) when the PfRON2 amino acid
sequence was used as template for Blastp analysis for
some Plasmodium species partial genomes. Plasmodium
species ron2 genes were located in homologous chromo-
somal regions, as shown by their high similarity and iden-
tity values (35%-88% and 16%-75%, respectively) at amino
acid level, similar ORF orientation and intron-exon pat-
tern. P. yoelii pyron2 downstream genes (Figure 1) were
excluded from analysis, given that this genome has not
been completely assembled.
PvRON2 is encoded by a single exon and transcribed in
blood-stage parasites
Plasmodium falciparum transcriptome analysis revealed
that PfRON2 begins its transcription after 35 hours,
reaching its maximum peak of expression 45 hours into
the erythrocytic cycle [46]. PCR amplification of
PvRON2 encoding sequence confirmed the transcript’s
presence in P. vivax VCG-1 strain parasites during the
blood stage (Figure 2A). This agreed with the results
obtained from P. vivax transcriptome analysis which
showed that PvRON2 is transcribed between hour
35 (TP7) and 40 (TP8) in the intraerythrocytic cycle,
similar to other proteins involved in invasion such as
PvMSP-1 [5]. When pvron2 gene gDNA and cDNA
sequences were compared, obtained from the three
amplification products overlapping by around 100 bp,
both are identical, thus confirming that this gene con-
sisted of a single 6,615bp exon. Recombinant clone
sequences were analysed using CLC DNA Workbench
(CLC bio) and the consensus sequence was deposited in
the GenBank with the ID: HQ825321.
Two substitutions and the insertion of a nucleotide
triplet were found when VCG-1 strain and Sal-1 refer-
ence strain nucleotide sequences were compared. Substi-
tutions in positions 1,241 and 1,814 produced a change
from valine to glycine (V414G) and histidine to proline
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Figure 1 Schematic representation of ron2 chromosomal localization (grey) and adjacent ORFs (white) in Plasmodium falciparum,
vivax, knowlesi, chabaudi, berghei and yoelii. The accession numbers for each ORF in PlasmoDB are shown. The length of the represented
chromosomal fragment and its localization within the genome in each species is shown on the right. Identity and similarity values at the amino
acid level between P. falciparum and P. vivax, as well as between P. vivax and P. knowlesi are pointed out.
Figure 2 cDNA amplification and PvRON2 schematic representation. A. PCR amplification from pvron2 gene RT-PCR product, with three sets
of primers as described in the Materials and Methods section. Lane 1. pvron2 region I (~2,176 bp). Lane 2. pvron2 region II (~2,580 bp). Lane 3.
pvron2 region III (~2,061 bp). Lane 4. molecular weight pattern. Lane 5. PvAMA-1 ectodomain amplification (positive control). Lane 6. Negative
control. B. PvRON2 protein representation. The signal peptide is shown in blue, the transmembrane domain (TMD) in dark grey, coiled-coil motifs
in light grey and red lines indicate conserved cysteines between Pf, Pv, Pk, Pc, Pb and Py. * represents polymorphic sites between Sal-1
(reference) and VCG-1 strains. The localization and sequence of inoculated peptides is marked.
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(H605P), respectively. The addition of a glutamic acid
(E)-encoding triplet (AAG) was found in position 1,487-
1,489nt (residue 496). Interestingly, these changes were
located in an interspecies variable region, spanning
around residues 50 to 850 [21], suggesting that this
region might be subjected to selective immune pressure.
Bioinformatics analysis of PvRON2 protein sequence
The PvRON2 complete protein sequence in the VCG-1
strain consists of 2,204 residues having a putative hydro-
phobic signal sequence within its first 17 amino acids
and a transmembrane domain (TMD) towards the
C-terminus between residues 2,087-2,109. The RON2
protein has similar lengths in other species, ranging
from 1,990 amino acids in P. chabaudi to 2,232 in
P. yoelii, as well as a similar domain organization,
including a signal peptide, a TMD and containing eight
conserved cysteines (Figure 2B) probably related to
common protein structural features.
PvRON2 contains two coiled coil a-helical motifs
(residues 145-184 and 1,651-1,703) (Figure 2B), charac-
terized by seven amino acid repeats (abcdefg) n with
hydrophobic residues located in positions a and d, and
residues (generally polar) in the remaining sites which
have been involved in protein-protein interactions.
These coiled coil motifs have been identified in several
important P. falciparum vaccine candidates such as
LSA-1, MSP-3, MSP6 and MSP11 [47,48]; such motifs
are recognized by naturally-acquired antibodies and
are also immunogenic in mice [49]. Interestingly, pep-
tide 35520 (containing part of the second coiled coil
a-helical motif) has induced an antibody response in
rabbits. Additionally, PvRON2 has two tandem repeat
(TR) regions located within the interspecies variable
sequence. Eight 11 amino acid long repeats (GADGK-
GYGPYG) are located between residues 258 and 345,
and the second tandem (GGYGNGGHE) is located
between residues 542-628, having 9 repeats (Figure
2B). TRs were mostly found in RON2 sequences from
different Plasmodium species and, even though the
DNA and protein sequences from the repeats varied
widely amongst RON2 proteins, there was close to
40% similarity between PvRON2 and PkRON2 repeats.
Such similarity between Pv and Pk was in agreement
with a close evolutionary relationship between simian
malarial parasites and the human P. vivax parasite.
TRs have been identified in different malarial antigens
such as the P. falciparum circumsporozoite protein
(CSP), the ring-infected erythrocyte surface antigen
(PfRESA) and the knob-associated histidine rich pro-
tein (KAHRP). These TRs could downregulate antibody
isotype maturation and high-affinity antibody produc-
tion in the specific case of malaria by acting as B-cell
superantigens, predominantly inducing a polyclonal
thymus-independent humoral response. T-independent
antibody responses are usually short lived, predomi-
nantly composed of IgM and IgG3 and have low affi-
nity, suggesting that these repeats are used during
invasion to distract the immune response, acting as
decoys or “smokescreens”, thereby masking the critical
epitopes [50,51]. Given all the above-mentioned data,
it would be important to assess the functional and
immunological implications of these repeat regions in
PvRON2.
PvRON2 is expressed in P. vivax schizonts
Polyclonal antibodies were produced against the protein
by immunizing rabbits with polymeric PvRON2-derived
peptides to assess PvRON2 expression and cellular loca-
lization in P. vivax schizonts. Polyclonal antibodies
detected two bands at around ~220 kDa and ~185 kDa
(Figure 3A), suggesting that PvRON2 can undergo pro-
teolytic processing, by contrast with that reported for
PfRON2 [21]. The predicted size for PvRON2 (240 kDa)
is slightly larger than that obtained from mobility on
SDS-PAGE (220 kDa). Interestingly, similar behaviour
has been described for TgRON2, suggesting anomalous
migration [52].
In many cases, it has been found that rhoptry proteins
are initially synthesized as pre-proteins and maturate
during transport [53]. It could be hypothesized that
such cleavage could serve to activate PvRON2 by reveal-
ing a functional domain or releasing the protein of para-
site surface or RBC membrane to allow successful
invasion. Additionally, pulse-chase analysis has shown
that TgRON2 is expressed as a pro-protein (~150 kDa)
which is cleaved to produce a ~120 kDa mature protein.
Even though it is not known which specific proteases
act in TgRON2 maturation, it has been suggested that
this protein can be cleaved by subtilisin 2 (TgSUB2)
[18]. Studies carried out with important P. falciparum
adhesins located on merozoite membrane, micronemes
or rhoptries, such as AMA-1, merozoite surface protein
(MSP), EBL, RBL and thrombospondin-related anon-
ymous protein (TRAP) families, contain a putative
rhomboid cleavage site within their TMD and putative
SUB-2 cleavage sites. COS-7 cell system studies have
revealed that A1427 residue substitution in the EBA-175
protein has prevented PfROM4-mediated shedding,
avoiding the release of EBA-175 from the merozoite sur-
face [54]. Similarly, substituting the GA motif (residues
which destabilize a-helices) closest to the TMD extra-
cellular end abolished specific cleavage (also predicted
as the site required for rhomboid recognition). Interest-
ingly, PvRON2 sequence analysis revealed a putative
rhomboid cleavage site between 2,101-2,104; this agreed
with the fact that sera recognized two fragments from
the protein, but additional studies are needed for
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assessing the importance of such processing, as well as
the identity of the responsible protease.
Immunofluorescence analysis of P. vivax schizonts
showed that PvRON2 had a dotted pattern typical of
apical organelles, such as rhoptries and micronemes
(Figure 3B). To examine their localization in detail, dual
labelling was performed using mouse polyclonal antibo-
dies against PvAMA-1 and PvRhopH3. It was found that
there was no co-localization between the PvAMA-1 pro-
tein (microneme marker) and PvRON2 (Figure 3C), sug-
gesting that PvRON2 is not present in micronemes. By
contrast, there was a small area of central localization
Figure 3 PvRON2 expression and apical localization. A. Anti-PvRON2 rabbit polyclonal antibodies detected two bands at around ~220 and
~185 kDa in parasite lysate by Western blot. Lane 1: pre-immune serum. Lane 2: hyper-immune serum. B. P. vivax schizonts incubated with anti-
PvRON2 polyclonal antibodies and revealed with FITC-labelled anti-rabbit IgG (green). Parasite nuclei were stained with DAPI (blue). C. Co-
localization study: schizonts were simultaneously incubated with anti-PvRON2 and anti-PvAMA-1 (top) or anti-PvRhopH3 (bottom) and detected
with FITC-labelled anti-rabbit and with rhodamine-labelled anti-mouse. Arrows indicate the typical dotted pattern displayed by apical organelles.
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between PvRhopH3 (rhoptry bulb marker) and PvRON2
suggesting that even though PvRON2 is located in the
rhoptries, it is not located in the rhoptry bulb, probably
forming part of the rhoptry neck, as has been described
for PfRON2 and TgRON2 proteins [18,21]. Recently, a
study that characterized the timing of expression and
subcellular location of Plasmodium homologues in some
T. gondii rhoptry proteins showed that P. berghei RON2
protein is located in merozoite and sporozoite rhoptries,
and presents a timing of expression comparable to the
one found in RAP2/3. These data strongly suggest an
essential role of RON2 protein during the invasion and
infection establishment in sporozoites [55].
Conclusions
As has been shown in the present study, RON2 is a
highly conserved protein among different Plasmodium
species. pvron2 gene consists of a single exon and is
transcribed and expressed in schizonts rhoptries at the
end of the erythrocytic cycle. Its similarity to PfRON2
(which forms a complex with PfAMA-1), as well as its
localization and expression time during the schizont
stage suggest a similar role in host cell invasion for
PvRON2, as that attributed to PfRON2.
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